ALTER is an open web-based tool to transform between different multiple sequence alignment formats. The originality of ALTER lies in the fact that it focuses on the specifications of mainstream alignment and analysis programs rather than on the conversion among more or less specific formats. In addition, ALTER is capable of identify and remove identical sequences during the transformation process. Besides its user-friendly environment, ALTER allows access to its functionalities in a programmatic way through a Representational State Transfer web service. ALTER’s front-end and its API are freely available at http://sing.ei.uvigo.es/ALTER/ and http://sing.ei.uvigo.es/ALTER/api/, respectively.

BackgroundLarge-sequencing cancer genome projects have shown that tumors have thousands of molecular alterations and their frequency is highly heterogeneous. In such scenarios, physicians and oncologists routinely face lists of cancer genomic alterations where only a minority of them are relevant biomarkers to drive clinical decision-making. For this reason, the medical community agrees on the urgent need of methodologies to establish the relevance of tumor alterations, assisting in genomic profile interpretation, and, more importantly, to prioritize those that could be clinically actionable for cancer therapy.ResultsWe present PanDrugs, a new computational methodology to guide the selection of personalized treatments in cancer patients using the variant lists provided by genome-wide sequencing analyses. PanDrugs offers the largest database of drug-target associations available from well-known targeted therapies to preclinical drugs. Scoring data-driven gene cancer relevance and drug feasibility PanDrugs interprets genomic alterations and provides a prioritized evidence-based list of anticancer therapies. Our tool represents the first drug prescription strategy applying a rational based on pathway context, multi-gene markers impact and information provided by functional experiments. Our approach has been systematically applied to TCGA patients and successfully validated in a cancer case study with a xenograft mouse model demonstrating its utility.ConclusionsPanDrugs is a feasible method to identify potentially druggable molecular alterations and prioritize drugs to facilitate the interpretation of genomic landscape and clinical decision-making in cancer patients. Our approach expands the search of druggable genomic alterations from the concept of cancer driver genes to the druggable pathway context extending anticancer therapeutic options beyond already known cancer genes. The methodology is public and easily integratable with custom pipelines through its programmatic API or its docker image. The PanDrugs webtool is freely accessible at http://www.pandrugs.org.Electronic supplementary materialThe online version of this article (10.1186/s13073-018-0546-1) contains supplementary material, which is available to authorized users.

BackgroundMass spectrometry is one of the most important techniques in the field of proteomics. MALDI-TOF mass spectrometry has become popular during the last decade due to its high speed and sensitivity for detecting proteins and peptides. MALDI-TOF-MS can be also used in combination with Machine Learning techniques and statistical methods for knowledge discovery. Although there are many software libraries and tools that can be combined for these kind of analysis, there is still a need for all-in-one solutions with graphical user-friendly interfaces and avoiding the need of programming skills.ResultsMass-Up, an open software multiplatform application for MALDI-TOF-MS knowledge discovery is herein presented. Mass-Up software allows data preprocessing, as well as subsequent analysis including (i) biomarker discovery, (ii) clustering, (iii) biclustering, (iv) three-dimensional PCA visualization and (v) classification of large sets of spectra data.ConclusionsMass-Up brings knowledge discovery within reach of MALDI-TOF-MS researchers. Mass-Up is distributed under license GPLv3 and it is open and free to all users at http://sing.ei.uvigo.es/mass-up.Electronic supplementary materialThe online version of this article (doi:10.1186/s12859-015-0752-4) contains supplementary material, which is available to authorized users.

Web services are the de facto standard in biomedical data integration. However, there are data integration scenarios that cannot be fully covered by Web services. A number of Web databases and tools do not support Web services, and existing Web services do not cover for all possible user data demands. As a consequence, Web data scraping, one of the oldest techniques for extracting Web contents, is still in position to offer a valid and valuable service to a wide range of bioinformatics applications, ranging from simple extraction robots to online meta-servers. This article reviews existing scraping frameworks and tools, identifying their strengths and limitations in terms of extraction capabilities. The main focus is set on showing how straightforward it is today to set up a data scraping pipeline, with minimal programming effort, and answer a number of practical needs. For exemplification purposes, we introduce a biomedical data extraction scenario where the desired data sources, well-known in clinical microbiology and similar domains, do not offer programmatic interfaces yet. Moreover, we describe the operation of WhichGenes and PathJam, two bioinformatics meta-servers that use scraping as means to cope with gene set enrichment analysis.

No abstract

No abstract

Colorectal cancer is a major health problem, where advances towards computer-aided diagnosis (CAD) systems to assist the endoscopist can be a promising path to improvement. Here, a deep learning model for real-time polyp detection based on a pre-trained YOLOv3 (You Only Look Once) architecture and complemented with a post-processing step based on an object-tracking algorithm to reduce false positives is reported. The base YOLOv3 network was fine-tuned using a dataset composed of 28,576 images labelled with locations of 941 polyps that will be made public soon. In a frame-based evaluation using isolated images containing polyps, a general F1 score of 0.88 was achieved (recall = 0.87, precision = 0.89), with lower predictive performance in flat polyps, but higher for sessile, and pedunculated morphologies, as well as with the usage of narrow band imaging, whereas polyp size < 5 mm does not seem to have significant impact. In a polyp-based evaluation using polyp and normal mucosa videos, with a positive criterion defined as the presence of at least one 50-frames-length (window size) segment with a ratio of 75% of frames with predicted bounding boxes (frames positivity), 72.61% of sensitivity (95% CI 68.99–75.95) and 83.04% of specificity (95% CI 76.70–87.92) were achieved (Youden = 0.55, diagnostic odds ratio (DOR) = 12.98). When the positive criterion is less stringent (window size = 25, frames positivity = 50%), sensitivity reaches around 90% (sensitivity = 89.91%, 95% CI 87.20–91.94; specificity = 54.97%, 95% CI 47.49–62.24; Youden = 0.45; DOR = 10.76). The object-tracking algorithm has demonstrated a significant improvement in specificity whereas maintaining sensitivity, as well as a marginal impact on computational performance. These results suggest that the model could be effectively integrated into a CAD system.

Supplementary data are available at Bioinformatics online.